Pliant Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Pliant Therapeutics Inc 's ROA in the second quarter of 2026?
Pliant Therapeutics Inc recorded a cumulative net loss of $-92 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -41.2%.

However, within the Healthcare sector 499 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3867, from total ROA ranking in the first quarter of 2026 at 4608.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-36.13 %	-41.24 %	-39.09 %	-33.78 %	-34.24 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-92	-113	-149	-175	-207
Return On Assets (TTM)	-41.2 %	-45.1 %	-52.11 %	-54.38 %	-57.81 %
PLRX's Total Ranking	# 3867	# 4608	# 4050	# 4133	# 4188
Total Assets (TTM) in million	191	203	225	277	300
Seq. Total Assets Change	-5.49 %	-10.05 %	-18.57 %	-7.75 %	-13.04 %
Seq. Net Income Change	-	-	-	-	-

PLRX's 5 Years Annual ROA >> Back to PLRX Management Effectiveness >> Compare PLRX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 201
Sector	# 500
Overall	# 3774

Return On Assets Statistics
High	Average	Low
-7.54 %	-38.12 %	-55.66 %
(Mar 31 2021)		(Jun 30 2025)

Financial Statements
Pliant Therapeutics Inc 's Assets	$ 191 million	PLRX's Balance sheet
Pliant Therapeutics Inc 's Income	$ -22 million	Quarterly PLRX's Income Statement
PLRX's Income by Division		See PLRX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-39.09 %	-45.49 %	96.18 %	60.06 %	-26.89 %
Total Assets in million	225	370	678	346	216
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-149	-210	161	-123	-97
Annual Return On Assets	-66.31 %	-56.87 %	23.78 %	-35.66 %	-45.02 %

PLRX's 5 Years Annual ROA >> Back to PLRX Management Effectiveness >> Compare PLRX ROA to its Competitors

More Return On Assets Ratios
PLRX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PLRX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PLRX's Competitors
Subscribers only: Roa for Pliant Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for PLRX's Customers

You may also want to know
PLRX's Roi	PLRX's Inventory Turnover Ratio	PLRX's Growth Rates	PLRX's Dividend Comparisons
	PLRX's Profitability Ratios	PLRX's Asset Turnover Ratio	PLRX's Dividend Growth
PLRX's Roe	PLRX's Valuation Ratios	PLRX's Financial Strength Ratios	PLRX's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-04T10:37:16+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.